Name: Convatec Activelife One-Piece Convex Pre-Cut Transparent Urostomy Pouch With Durahesive Skin Barrier,Stoma Opening: 1 (25Mm),5/Pack,175794
Brand: CONVATEC
SKU: 525-127917
Price: 52.99 USD
Availability: InStock

Convatec Activelife One-Piece Convex Pre-Cut Transparent Urostomy Pouch With Durahesive Skin Barrier,Stoma Opening: 1 (25Mm),5/Pack,175794 - 525-127917

By CONVATEC

$52.99

(401 Reviews)

Model

525-127917

Store

Health Products For You

Manufacturer

CONVATEC

Detail

ConvaTec ActiveLife One-Piece Convex Pre-Cut Transparent Urostomy Pouch With Durahesive Skin Barrier combines the skin barrier and the pouch into one simple, easy-to-manage system. Durable comfort panel is designed to be odour-proof and quiet to maintain discretion. Tap at bottom allows for easy draining of urine.

Category

Ostomy

A joint letter from six major medical organizations calls on Congress to ensure patients can access affordable, quality health care. The organizations -- ACP, the American Academy of Family Physicians, American Academy of Pediatrics, American College of Obstetricians and Gynecologists, American Psychiatric Association and the American Osteopathic Association -- represent about 600,000 physicians in the U.S. One prominent issue the organizations discussed in the letter was the Medicare Physician Fee Schedule. The organizations urged Congress to pass the Supporting Medicare Providers ...

>Read More

The Renal Physicians Association, the American Society of Nephrology and more than 100 other medical groups have sent a letter to Congress asking legislators to limit the impact of a planned cut in Medicare payments to physicians. Changes in the final rule for the Medicare Physician Fee Schedule (MPFS) call for a 4.5% reduction in payments starting Jan. 1. The letter asks lawmakers to prevent the entire 4.5% reduction to Medicare payment rates from being implemented on January 1, 2023. This desperately needed relief will help provide financial stability for practices until permanent ...

>Read More

PHILADELPHIA -- Significant and distinct shifts in critical cellular players were seen among patients with rheumatoid arthritis-associated interstitial lung disease, according to an ongoing study presented at ACR Convergence 2022. We know that monocytic and granulocytic myeloid derived suppressor cells may impact disease, as well as alternately activated monocytes, Jill Poole, MD, professor of medicine and division chief in the division of allergy at the University of Nebraska Medical Center, said during the presentation. Peripheral blood was collected from 15 ...

>Read More

Clinical outcome assessments currently used for people with Lennox-Gastaut syndrome and Dravet syndrome were not fit for evaluating non-seizure outcomes, researchers said, prompting the development of a global clinical impression measure. Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) are rare developmental and epileptic encephalopathies that involve treatment-resistant seizures, as well as cognitive and neurological delays or declines, Mahnaz Asgharnejad, PharmD, vice president and global program leader at Takeda Pharmaceuticals, and colleagues wrote in a poster ...

>Read More

Patients with ocular monkeypox experienced delays in treatment, prolonged illness, hospitalization and, in one case, significant vision impairment, according to a CDC report. Ocular monkeypox is rare but can be a sight-threatening condition, study author Shama Cash-Goldwasser, MD, told Healio/OSN. Anyone with monkeypox can develop ocular monkeypox if the virus gets into the eye, which can occur through autoinoculation of the eyes -- or if a patient touches a lesion and then touches their eye. The report outlines five cases of ocular monkeypox reported from July ...

>Read More

CMS has proposed new rules intended to improve access to health information and streamline processes that are involved with prior authorization, according to a press release from the agency. CMS is committed to strengthening access to quality care and making it easier for clinicians to provide that care, Chiquita Brooks-LaSure, an administrator at CMS, said in the release. The prior authorization and interoperability proposals we are announcing today would streamline the prior authorization process and promote health care data sharing to improve the care ...

>Read More

The FDA on Thursday expanded its emergency use authorization of Moderna and Pfizer-BioNTechs omicron-targeting bivalent COVID-19 boosters to include children aged as young as 6 months in the United States. In October, the agency granted emergency use authorizations (EUAs) for Pfizers bivalent booster for children aged 5 to 11 years and Modernas bivalent booster for children aged 6 to 11 years and adolescents aged 12 to 17 years. More children now have the opportunity to update their protection against COVID-19 with a bivalent COVID-19 vaccine, and we encourage ...

>Read More

Product Details for 525-127917